Adult skeletal muscle tolerates a lack of the coenzyme nicotinamide adenine dinucleotide (NAD), according to a study led by scientists at the University of Copenhagen. Their results suggest that adverse effects previously associated with congenital NAD depletion in this tissue may be due to impaired muscle development rather than to a deficiency of this molecule. Read More
Astrazeneca plc recently reported new preclinical data regarding their KRAS G12D inhibitor AZD-0022, currently in phase I/II clinical studies. The company presented the pharmacokinetic and pharmacodynamic profiling of the compound with the aim to push forward with its clinical development. Read More
Mammoth Biosciences Inc. has nominated its first clinical development candidate – MB-111 – a potential one-time treatment for patients with very high triglycerides, including familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia. IND-enabling studies are on track to begin this year. Read More
Nutshell Therapeutics (Shanghai) Co. Ltd. has received IND clearance from the FDA to initiate a phase I trial in the U.S. with NTS-071 for anticipated use in solid tumors with a p53 Y220C mutation. The trial is expected to begin in the second half of this year. Read More
Tyligand Bioscience Ltd. has reported data on TSN-222, their new cyclic dinucleotide designed as a dual-action tumor immune agonist (DATIA) compound. Read More
While current influenza vaccines primarily target the variable hemagglutinin protein, the slower-evolving neuraminidase presents a promising target for the development of new vaccines providing broader protection. Read More
Revolution Medicines Inc. has disclosed macrocyclic compounds acting as GTPase KRAS (G12V mutant) inhibitors reported to be useful for the treatment of cancer. Read More
Programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF) are often co-expressed in the tumor microenvironment. The combination of anti-PD-1 and anti-VEGF agents has been evaluated in patients with advanced non-small-cell lung cancer, with promising results from agents like ivonescimab, a PD-1/VEGF bispecific antibody. Read More
Quantx Biosciences US Inc. has synthesized interleukin-17A/A homodimer and/or IL-17A/F heterodimer inhibitors reported to be useful for the treatment of autoimmune and inflammatory diseases. Read More
Haisco Pharmaceutical Group Co. Ltd. has identified peptide-drug conjugates comprising a peptide targeting integrin αvβ3 (vitronectin) covalently bound to a cytotoxic drug through a linker reported to be useful for the treatment of cancer. Read More
Human papillomavirus (HPV), particularly the high-risk HPV16 subtype, is a major driver of certain cancers, including cervical, oropharyngeal, anal and penile cancers. The E6 and E7 proteins produced by HPV16 are known to play critical roles in the development of these malignancies, making them attractive targets for therapeutic interventions. Read More
Each year, acute kidney injury affects more than 13 million people and leads to nearly 2 million deaths. It can occur, for example, in cancer patients taking nephrotoxic cisplatin chemotherapy and in individuals who suffer sepsis or ischemic stroke. Read More
Shanghai Yiweikang Pharmaceutical Co. Ltd. has divulged camptothecin derivatives acting as DNA topoisomerase I inhibitors reported to be useful for the treatment of cancer. Read More
Abnormal aggregation of α-synuclein is thought to contribute to the pathology of Parkinson’s disease, the second most frequent neurodegenerative disorder. Therefore, developing drugs that prevent such aggregation could be effective for slowing or even preventing the disease. Read More
Starg (Wuhan) Pharmaceutical Technology Co. Ltd. has described Werner syndrome ATP-dependent helicase (WRN; RECQ3; RECQL2) inhibitors reported to be useful for the treatment of cancer. Read More
Additional early-stage research and drug discovery news in brief, from: Bio-Path, Longhorn Vaccines and Diagnostics, Marvel Biosciences, Nodthera. Read More
